Today
+1.15%
5 Days
+3.22%
1 Month
+9.60%
6 Months
+5.39%
Year to Date
-0.28%
1 Year
+4.66%
• Danaher narrowed its full-year core revenue growth projections following second-quarter results. • Outgoing leadership announced a transition alongside subsequent disclosures of executive share sales. • The company reported latest annual revenue of $24.57B and net profit of $3.61B.
• ResMed faces volatility from Astral ventilator sales suspensions and strategic portfolio adjustments. • Management reports under-penetrated sleep apnea markets despite ongoing debate over GLP-1 therapies. • The company generated $5.65B in annual revenue with net profit reaching $1.52B.
• CVS Health gained following an institutional upgrade and strong earnings visibility. • Market rotation into defensive healthcare sectors supported buying interest amid broader volatility. • Annual revenue reached $402.07 billion with a net profit of $1.77 billion.
• Capital rotated from defensive healthcare stocks into higher-beta growth sectors in June. • Medtronic’s share price declined following disappointing fiscal 2027 forward-looking guidance. • FTSE Russell index reconstitution and ex-dividend adjustments increased stock trading volatility.
• Abbott's share price rose due to diabetes and oncology news. • CE Mark for dual glucose-ketone sensing technology approved. • Strong earnings, revenue, and maintained full-year guidance.
• Medtronic reported strong Q4 FY26 revenue exceeding expectations. • Company announced dividend increase and optimistic FY27 outlook. • Strategic moves include FDA filings, acquisitions, and investments.
Medtronic (MDT) Fiscal Q1 2027 Earnings Call: Revenue Growth and Guidance Raised


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.49% |
| BlackRock Institutional Trust Company, N.A. | 5.22% |
| State Street Investment Management (US) | 4.80% |
| JP Morgan Asset Management | 3.16% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.99% |
| Investment Advisor/Hedge Fund | 29.82% |
| Research Firm | 3.63% |
| Pension Fund | 2.17% |
Related Instruments
Popular Instruments